YK Bioventures Opportunities GP I, LLC 13D and 13G filings for CERo Therapeutics Holdings, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-12-17 7:26 pm Sale | 2024-12-13 | 13G | CERo Therapeutics Holdings, Inc. CERO | YK Bioventures Opportunities GP I, LLC | 9 0.000% | -11,302 (-99.92%) | Filing |
| 2024-11-14 8:18 pm Purchase | 2024-08-02 | 13G | CERo Therapeutics Holdings, Inc. CERO | YK Bioventures Opportunities GP I, LLC | 11,310 15.000% | 11,310 (New Position) | Filing |